reactive oxygen species

Byaibio

Reactive oxygen species (ROS) are highly reactive oxygen-containing molecules that act as both signaling mediators and damaging oxidants, with generation often increasing downstream of interventions such as mitochondrial genome editing and nanoplatform activation. They are central to oxidative stress biology and are implicated in mitochondrial dysfunction, macrophage inflammation, apoptosis, oocyte deterioration, and infection-associated tissue injury. In therapy, ROS are deliberately induced by photodynamic and chemo-photodynamic systems, including tc nanodrugs, iridium iii complexes, and doxorubicin, where localized ROS accumulation can amplify mitochondrial damage and cell death. Conversely, ROS can also be therapeutically suppressed or scavenged by agents such as ca7 and pat nps to reduce NETosis-related injury, oral ulcer damage, and other redox-driven pathology. Recent studies highlight spatiotemporal control of ROS bursts by nanozymes and mitochondria-targeted platforms, including sustained intracellular ROS amplification and redox-homeostasis disruption. Overall, ROS are a mechanistically versatile effector class with context-dependent roles in cancer therapy, inflammatory disease, reproductive aging, and mitochondrial medicine.

Cancer

  • A 2026 Chemical Science study of spatiotemporally regulated mitochondrial genome editing via an enzyme- and NIR-activated CRISPR/Cas9 nanoplatform reported increased ROS generation as a downstream effect (PMID:41584446).
  • A 2026 ACS Applied Materials & Interfaces study showed irradiation-dependent ROS generation from tc nanodrugs, supporting photodynamic antitumor activity and ferroptosis/immunotherapy enhancement (PMID:41918284).
  • A 2026 Inorganic Chemistry paper found that iridium iii complexes generated strong ROS and triggered localized ROS accumulation after cellular uptake, contributing to apoptotic cell death (PMID:41941352).
  • A 2026 Molecular Pharmaceutics study reported that doxorubicin-induced ROS production synergized with paeoniflorin-mediated mitochondrial dysfunction to enhance apoptosis in lung cancer cells (PMID:41810719).
  • A 2026 Science Advances study linked C15ORF48 knockdown to increased ROS in breast cancer cells treated with AC, consistent with blunted ROS accumulation by C15ORF48 and chemotherapy resistance in TNBC (PMID:41931605).

Mitochondrial dysfunction and inflammatory disease

  • Excessive ROS were described as a pathogenic mechanism contributing to mitochondrial dysfunction, macrophage inflammation, and cell death in a 2026 Antioxidants & Redox Signaling study (PMID:41894156).
  • A 2026 International Journal of Pharmaceutics: X review emphasized that ROS contribute to mitochondrial dysfunction and that therapeutic delivery to mitochondria may alleviate this damage (PMID:41675221).
  • A 2026 Advanced Science paper described a hydrogen-releasing nanozyme that generates exogenous hydroxyl radicals and sustains an intracellular ROS burst through mitochondrial ROS amplification, disrupting redox homeostasis for self-sustaining catalytic immunotherapy (PMID:41961470).
  • A 2026 Molecular Biomedicine study showed that suppressing the ROS-NETosis axis with CA7 reduced ROS production and ameliorated acute liver failure-related injury (PMID:41973300).

Reproductive aging and oxidative damage

  • A 2026 GeroScience review identified ROS-induced oocyte deterioration and oxidative damage as mechanisms underlying oocyte aging (PMID:41952008).
  • The same review placed ROS among environmental and endogenous stressors that drive reproductive potential decline, reinforcing oxidative stress as a key aging pathway (PMID:41952008).

Infection, ulcers, and local oxidative stress control

  • A 2026 Redox Report review stated that excessive ROS generation induces oxidative stress in arbovirus infections, linking ROS to infection-associated pathology (PMID:41986933).
  • A 2026 Journal of Materials Chemistry B study reported that ROS were locally overloaded in oral ulcers and scavenged by PAT nanoparticles, supporting antioxidant wound therapy (PMID:41989033).
  • A 2026 Bioactive Materials study noted that ROS generation increased after activation of a nanoplatform, consistent with ROS-linked immunotherapeutic effects in acute lung injury (PMID:41810016).